Hepatitis C: latest news

Hepatitis C resources

Hepatitis C features

Hepatitis C in your own words

Hepatitis C news from aidsmap

More news

Hepatitis C news selected from other sources

  • Hep C… and Me?

    A hookup mentioned hepatitis C. It made me question my life. Should I be getting tested for hep C? Did I need to be asking tricks about their status? Was my blissful ignorance about hep C a problem?

    29 May 2015 | BETA blog
  • Philip Christopher Baldwin talks about living with hep C in the gay community

    I did not have the courage to tell people that I had Hep C, worried that others would gossip about me. There were no role models in the media for co-infection with HIV and Hep C, which made it harder to be open. I had fought so hard to be an out gay man, and now I was hiding something that was inextricably linked to my sexuality, to my identity and to my core sense of who I am.

    13 May 2015 | QX
  • Hepatitis C common among HIV-positive patients in sub-Saharan Africa

    Around 3% of people in sub-Saharan Africa have been infected with HCV infection, rising to 5.7 per cent in individuals with HIV. The findings will inform the global debate about how treatment should be made available to all those who need it.

    06 May 2015 | Eurekalert Inf Dis
  • Civil Society Groups Tell UNITAID: Support access mechanisms led by civil society, not the pharmaceutical industry

    Letters from global groups express deep concerns about the Medicines Patent Pool’s entry into hepatitis C treatment.

    05 May 2015 | Hep C Coalition
  • Is There Any Good Reason Left to Delay Hepatitis C Treatment?

    Physicians increasingly argue that the best choice is to get rid of hepatitis C right away. But your insurance company may not agree. How risky is it to wait for treatment?

    17 April 2015 | Poz
  • EECA CAB positions in regards to Janssen, BMS, Gilead and ViiV policy

    EECA CAB (Community Advisory Board in Eastern Europe and Central Asia) has published its positions in regards to Janssen, BMS, ViiV and Gilead policy. The positions were developed on the results of the meetings with the companies during last year.

    09 March 2015 | EATG
  • Study: Door-to-door campaign linked hepatitis C patients to care

    Working on the streets in medically underserved Philadelphia neighborhoods, members of the Do One Thing program have been able to identify residents chronically infected with hepatitis C and help them overcome the hurdles that prevent people from being cured, according to a new study in the Journal of General Internal Medicine.

    16 February 2015 | Eurekalert Inf Dis
  • Healthcare: The race to cure rising drug costs

    The controversy over hepatitis C drug prices has highlighted the broader question of whether pharmaceutical companies can defend their premium pricing model in the world’s biggest healthcare market. It is a battle that big pharma risks losing, raising questions over the economic model of an industry that relies heavily on US profits to reward investors and finance new drugs.

    13 February 2015 | Financial Times
  • Achillion Achieves 100% SVR12 in Phase 2 Trial Evaluating 6-Week Combination Treatment With ACH-3102

    Achillion Pharmaceuticals, Inc. today announced updated interim results from the ongoing interferon-free, ribavirin-free, Phase 2 study to evaluate the efficacy, safety, and tolerability of six weeks of 50 mg of ACH-3102 and 400 mg of sofosbuvir, a marketed nucleotide polymerase inhibitor, in treatment-naïve genotype 1 HCV-infected patients.

    09 February 2015 | Achillion press release
  • Portugal agrees to treat 13,000 hepatitis C patients

    The Portuguese government has agreed to treat up to 13,000 people infected with hepatitis C in the next three years, Portuguese Minister of Health Paulo Macedo said on Friday.

    09 February 2015 | Xinhua
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.